一种犬源干扰素α制备工艺开发及体内外活性研究  

Development of a Preparation Process for Canine Interferon Alpha and Study on its in vitro and in vivo Activities

作　　者：于丹[1] 孙盼盼 孙文琪 李晓颖 李德山 YU Dan;SUN Panpan;SUN Wenqi;LI Xiaoying;LI Deshan(Jiangsu Kangyuan Pharmaceutical Co.,Ltd.,Lianyungang 222047,China)

机构地区：[1]江苏康缘药业股份有限公司,江苏连云港222047

出　　处：《生物化工》2024年第3期98-101,共4页Biological Chemical Engineering

摘　　要：目的:开发一种高活性的犬源干扰素α(CIFNα)制备工艺。方法:构建CIFNα表达载体,筛选表达菌株,通过诱导表达包涵体,采用优化后的纯化工艺对包涵体进行纯化,获得高纯度CIFNα,通过体外活性测定及体内攻毒治疗实验,考察CIFNα的生物活性。结果:制备的CIFNα纯度在95%以上,体外活性测定中比活为8.39×10~6 U/mg,优于已经上市的CIFNα;体内攻毒结果表明,制备的CIFNα具有显著的治疗犬细小病毒疾病的作用。结论:开发了操作简便、安全、有效、质量可靠的CIFNα制备工艺,适用于商业规模化生产,为CIFNα的实际生产和应用提供了技术支持。Objective:Development of a high-activity canine-derived interferon alpha(CIFNα)preparation process.Methods:The CIFNαexpression vector is constructed,and the expressing strain is screened.The inclusion bodies are induced to express,and then the optimized purification process for the inclusion bodies is used to obtain high-purity CIFNα.The biological activity of CIFNαwas investigated by in vitro activity measurement and in vivo challenge therapy experiment.Results:The purity of CIFNαis over 95%,and the specific activity measured in vitro is 8.39×106 U/mg,which is slightly better than the specific activity of the marketed CIFNα;the in vivo results show that it had a significant effect against canine parvovirus disease.Conclusion:A simple,safe,effective,and reliable preparation process for CIFNαhas been developed,suitable for commercial large-scale production.This provides strong support for the practical production and application of CIFNα.

关 键 词：犬源干扰素α 包涵体 变性复性 层析 

分 类 号：Q511[生物学—生物化学] S852.655[农业科学—基础兽医学]